Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tachyon Therapeutics Inc. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The portfolio's activity is confined to 1 distinct examiner and 1 distinct art unit, reflecting a specific prosecution path. This focus indicates that the company's current intellectual property efforts are concentrated within the Biotechnology & Pharmaceuticals sector. Such a structure allows for a dedicated prosecution strategy but offers no internal comparison points for examiner behavior.
The busiest examiner, RZECZYCKI, PHILLIP MATTHEW, is currently reviewing 1 pending office action. As this 1 pending matter represents the entirety of the company's pending workload, the prosecution timeline is subject to the review pace of this individual. The involvement of 1 distinct art unit further underscores the specialized nature of the pending application. Legal teams should prioritize understanding the specific prior art interpretations favored by RZECZYCKI, PHILLIP MATTHEW within the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554283 | TREATMENT OF CANCER WITH KDM4 INHIBITORS | RZECZYCKI, PHILLIP MATTHEW | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554283 | TREATMENT OF CANCER WITH KDM4 INHIBITORS | RZECZYCKI, PHILLIP MATTHEW | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial